(70 days)
The ARCUATE™ Vertebral Augmentation System is indicated for the treatment of painful pathological fractures of the vertebral body. Vertebral compression fractures may result from osteoporosis, benign lesions and/or malignant lesions such as metastatic cancers and myeloma.
The ARCUATE™ Vertebral Augmentation System consists of a variety of manual instruments which provides physicians with a means to percutaneously deliver polymethylmethacrylate (PMMA) bone cement to the spine in vertebroplasty procedures. The ARCUATE™ Vertebral Augmentation System kits are packaged with VISIOPLAST™ Spine Cement, which has been previously cleared by the FDA for use in the treatment of painful vertebral compression fractures.
The provided text is a 510(k) summary for the ARCUATE Vertebral Augmentation System, which is a submission to the FDA for market clearance. It primarily focuses on demonstrating substantial equivalence to previously cleared devices rather than presenting a de novo study with specific performance criteria and results.
Therefore, much of the requested information (acceptance criteria, device performance, sample sizes, expert ground truth, adjudication, MRMC study, standalone performance, training set details) is not available in this document.
The document indicates that the purpose of this particular 510(k) application is to "include additional instruments to the previously cleared ARCUATE™ Vertebral Augmentation System (K063248)". This suggests that the substantial equivalence argument relies on the existing clearance of the base system and its components.
Here's a breakdown of what can be extracted and what is missing:
1. A table of acceptance criteria and the reported device performance
- Not Available: This document does not present specific performance criteria or a study demonstrating the device meets them. The device is a set of manual instruments for delivering bone cement, and the substantial equivalence is based on its similarity to other legally marketed systems. Performance data related to mechanical properties or clinical outcomes would typically be found in direct studies, which are not detailed here for this 510(k) submission.
2. Sample sized used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Not Available: No test set or associated data is described in this summary, as it's a substantial equivalence submission for additional instruments, not a de novo clearance requiring new clinical performance data.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- Not Available: No test set or ground truth establishment is mentioned.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- Not Available: No test set or adjudication process is described.
5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- Not Applicable/Not Available: This is a submission for a medical device (surgical instruments and cement delivery system), not an AI-powered diagnostic tool. Therefore, an MRMC study comparing human readers with and without AI assistance is irrelevant and not mentioned.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- Not Applicable/Not Available: This is not an algorithm or AI product.
7. The type of ground truth used (expert concensus, pathology, outcomes data, etc)
- Not Available: No ground truth establishment is described.
8. The sample size for the training set
- Not Available: No training set is applicable or described.
9. How the ground truth for the training set was established
- Not Available: No training set or ground truth establishment is applicable or described.
Summary of the 510(k) Content:
- Device: ARCUATE™ Vertebral Augmentation System (specifically, additional instruments for a previously cleared system).
- Purpose: Percutaneously deliver polymethylmethacrylate (PMMA) bone cement to the spine for vertebroplasty procedures.
- Indication: Treatment of painful pathological fractures of the vertebral body (due to osteoporosis, benign lesions, and/or malignant lesions).
- Substantial Equivalence: Demonstrated by comparison to several previously cleared systems and the VISIOPLAST™ Spine Cement (K042415) packaged with the system. The focus is on the device's design and intended use being similar to existing, cleared products.
- Regulatory Clearance: K070527 was cleared on May 4, 2007.
To find the missing information (performance criteria, specific study details), one would typically need to review the original 510(k) submission for the predicate devices that established the foundational clearance for vertebroplasty systems and PMMA bone cement, or the full K063248 submission for the ARCUATE™ Vertebral Augmentation System itself, if it contained such data. This specific document K070527 is an amendment for additional instruments, relying on prior clearances.
§ 888.3027 Polymethylmethacrylate (PMMA) bone cement.
(a)
Identification. Polymethylmethacrylate (PMMA) bone cement is a device intended to be implanted that is made from methylmethacrylate, polymethylmethacrylate, esters of methacrylic acid, or copolymers containing polymethylmethacrylate and polystyrene. The device is intended for use in arthroplastic procedures of the hip, knee, and other joints for the fixation of polymer or metallic prosthetic implants to living bone.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance Document: Polymethylmethacrylate (PMMA) Bone Cement.”